RxDoctor Payments Data

Rama Garimella, MD

Cardiovascular Disease · Cary, NCNPI 1740278415

Payments from drug & device makers

$14,229in general payments, 2019–2025

Across 954 payments — averaging $14.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • AstraZeneca$1K
  • E.r. Squibb & Sons, L.L.C.$1K
  • Amgen$1K
  • Novartis$1K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
  • plus $6K from 36 others

What the payments were for

  • Food & beverage$14,180100%
  • Education$490%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,229 in reported general payments places this provider in the 75th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$454,808
Medicare patients
967
Services billed
5,950

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,034$980,276
Repatha SureclickEvolocumab399$291,538
XareltoRivaroxaban274$261,898
JardianceEmpagliflozin231$179,260
FarxigaDapagliflozin Propanediol153$108,311
EntrestoSacubitril/Valsartan105$87,470
Praluent PenAlirocumab72$49,794
Dofetilide159$44,120
MultaqDronedarone Hcl31$43,898
OzempicSemaglutide24$22,063
VascepaIcosapent Ethyl47$21,935
NexlizetBempedoic Acid/Ezetimibe33$20,092
NexletolBempedoic Acid22$16,948
Repatha SyringeEvolocumab15$16,931
BrilintaTicagrelor16$16,584

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$188$980,2761,034 claims
Johnson & JohnsonXarelto$1,653$261,898274 claims
Boehringer IngelheimJardiance$703$179,260231 claims
AstraZenecaFarxiga, Brilinta$1,487$124,895169 claims
NovartisEntresto$1,271$87,470105 claims
Sanofi-aventis U.S. LLCMultaq$994$43,89831 claims
Esperion Therapeutics, Inc.Nexlizet, Nexletol$992$37,04055 claims
Novo NordiskOzempic$491$22,06324 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Cary

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →